MarginsXMarginsX
Home › Markets › Health Care › VERU

Veru Inc. (VERU)

VERU trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.08
-0.48% on the day
Market cap
$35.5M
Nano cap
Revenue · 2024
$16.9M
+3.6% on 2023
Net income · 2024
-$37.8M
-223.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2024-09-30, https://www.sec.gov/Archives/edgar/data/863894/000143774924037576/0001437749-24-037576-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-09-30.

Profile

FieldValue
TickerVERU on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000863894
SEC industry codePharmaceutical Preparations
Incorporated inWI

Financials · 2024

LineValue
Revenue$16.9M
Net income-$37.8M
Operating income-$36.2M
Net margin-223.9%
Operating margin-214.2%
Revenue growth+3.6%
Cash$24.9M
Total assets$60.4M
P/E (computed)Net income was not positive
P/S (computed)2.1×

Warning signs

Cash runway
11.0 months
$23.9M cash at June 30, 2026
Share count, 1 year
+16.4%
2025-08-07 to 2026-08-06 · +88.9% over 3 years
Going-concern doubt
Yes
10-Q filed August 10, 2026
Insider net buying, 12 months
$5K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least twelve months subsequent to the issuance date of these financial statements. 10 Table of Contents Note 3 Discontinued Operations On December 30, 2024, the Company and PCHC Limited (collectively, the Sellers ) entered into a Stock and Asset Purchase Agreement (the Purchase Agreement ) "
10-Q 2026-08-10
Cash and burn$23.9M cash; operating cash flow -$6.5M a quarter.Report 2026-06-30
Shares outstanding17,050,320 (2026-08-06); 14,650,392 a year earlier; 90,280,439 three years earlier. 3y figure adjusted for split (1-for-10 overall).Cover page 2026-08-06
Reverse splits, 3 years1; latest 1-for-10 on 2025-08-11Source 2025-08-11
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-07-02
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCherry Bekaert LLP, Atlanta, Georgia, United StatesPCAOB Form AP 2025-12-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $5K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-06-30
Not filed-$7.0M-$5.5M$23.9MNo debt tagsNeeds four quarters10-Q 2026-08-10
Q2 2026
2026-03-31
Not filed-$2.7M-$8.9M$27.6MNo debt tagsNeeds four quarters10-Q 2026-08-10
Q1 2026
2025-12-31
Not filed-$5.3M-$6.2M$33.0MNo debt tagsNeeds four quarters10-Q 2026-08-10
Q4 2025
2025-09-30
Not filed$1.5M-$5.5M$15.8MNo debt tagsNeeds four quarters10-K 2025-12-17
Q3 2025
2025-06-30
$0-$7.3M-$5.5M$15.0MNo debt tagsNeeds four quarters10-Q 2025-08-12
Q2 2025
2025-03-31
$0-$7.9M-$7.7M$20.0MNo debt tagsNeeds four quarters10-Q 2025-05-08
Q1 2025
2024-12-31
Not filed-$8.9M-$11.3M$26.6MNo debt tagsNeeds four quarters10-Q 2026-08-10
Q4 2024
2024-09-30
$6.7M-$8.5M-$4.4M$24.9MNo debt tags$16.9M10-K 2024-12-16

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-07-02
Latest annual report
FORM 10-K
10-K2025-12-17
Latest quarterly / interim
FORM 10-Q
10-Q2026-08-10
Latest current report8-K2026-09-08
Latest proxyDEFA14A2026-01-28

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.4%
1 month-4.6%
3 months-22.6%
Year to date-2.3%
1 year-16.7%
From 52-week high-50.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
TELOTelomir Pharmaceuticals Inc.$0.4810-1.96%$35.4M
OSTXOS Therapies Incorporated$0.6807-8.63%$35.4M
ATHEAlterity Therapeutics Limited$1.960.00%$35.7M
RNTXRein Therapeutics Inc.$0.4000-27.55%$34.5M
GRCEGrace Therapeutics Inc.$1.75-3.31%$36.8M
SERSerina Therapeutics Inc.$1.42+2.16%$37.7M
BMEABiomea Fusion Inc.$0.5201-10.67%$37.8M
HYPDHyperion DeFi Inc.$2.47-4.26%$38.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier